Clinical Trials Logo

Type II Diabetes Mellitus clinical trials

View clinical trials related to Type II Diabetes Mellitus.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05719155 Completed - Clinical trials for Type II Diabetes Mellitus

Pharmacokinetics and Safety/Tolerability of CKD-379

Start date: February 27, 2023
Phase: Phase 1
Study type: Interventional

A study to compare the pharmacokinetics and safety/tolerability between CKD-379 tablet and D759, D745, D150 combination

NCT ID: NCT05544214 Completed - Clinical trials for Type II Diabetes Mellitus

Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects

CKD-371
Start date: October 21, 2022
Phase: Phase 1
Study type: Interventional

This study is an open-label, randomized, single dose, crossover study to evaluate the pharmacokinetics, safety and tolerability of CKD-388 in healthy subjects

NCT ID: NCT05452525 Completed - Clinical trials for Type II Diabetes Mellitus

Pharmacokinetics and Safety/Tolerability Profile of CKD-379

Start date: July 26, 2022
Phase: Phase 1
Study type: Interventional

A study to compare the pharmacokinetics and safety/tolerability between CKD-379 tablet and D759, D745, D150 combination

NCT ID: NCT05274880 Completed - Clinical trials for Type II Diabetes Mellitus

Study to Evaluate the Food Effect on Pharmacokinetics Profile and Safety of CKD-393

Start date: June 21, 2022
Phase: Phase 1
Study type: Interventional

Study to evaluate the food effect on pharmacokinetic profiles and safety of CKD-393 in healthy volunteers

NCT ID: NCT04790526 Completed - Clinical trials for Type II Diabetes Mellitus

Dose Response of Eccentric Exercise on Glycemic Control in Type II Diabetes Mellitus

Start date: July 12, 2021
Phase: N/A
Study type: Interventional

The major aim of this project to check the dose response of eccentric exercise in reduction of glycemic index in type II Diabetes Mellitus. This study aim to check the effect of eccentric exercises on Glycemic index, quality of life, strength, exertion, balance and proprioception in type II Diabetes Mellitus patients

NCT ID: NCT04665284 Completed - Clinical trials for Type II Diabetes Mellitus

Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus

SAFE-PAK
Start date: June 1, 2019
Phase: Phase 4
Study type: Interventional

To compare the safety and efficacy of empagliflozin versus other treatments in Pakistani Muslim population with type II diabetes mellitus.

NCT ID: NCT03615755 Completed - Diabetic Foot Ulcer Clinical Trials

Short Duration Hyperbaric Oxygen Therapy to Improve HbA1c, Leukocyte, and Serum Creatinine

Start date: December 27, 2016
Phase: N/A
Study type: Interventional

The investigators want to evaluate the short duration HBOT can improve glycohemoglobin (HbA1c) levels, leukocyte count, and serum creatinine levels in patients with DFU (diabetic foot ulcer) Wagner 3-4.

NCT ID: NCT03550378 Completed - Renal Insufficiency Clinical Trials

A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well Tolerated

Start date: June 29, 2018
Phase: Phase 2
Study type: Interventional

A study to look at the effect MEDI0382 has on blood sugar in people with type 2 diabetes and kidney problems and also to check that MEDI0382 is well tolerated.

NCT ID: NCT03084965 Completed - Clinical trials for Type II Diabetes Mellitus

Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan

Start date: May 12, 2017
Phase:
Study type: Observational

Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan.

NCT ID: NCT03059719 Completed - Clinical trials for Type II Diabetes Mellitus

Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus

Start date: April 8, 2015
Phase: Phase 1
Study type: Interventional

This is a randomized, opened, positive drug-controlled (Exenatide, Byetta), sequential parallel group, multiple dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of twelve once-weekly subcutaneous doses of PB-119 to subjects with type 2 diabetes mellitus (T2DM).